Synthetic stable gastric pentadecapeptide (15-amino-acid partial sequence derived from a protein in human gastric juice)
BPC-157
Restricted / Rx-onlyaka Body Protection Compound 157, PL 14736, PL-10, Bepecin, pentadecapeptide BPC 157
BPC-157 is a synthetic pentadecapeptide based on a fragment of a protein found in gastric juice. The bulk of its evidence is preclinical (rodent and in-vitro), with only very limited, uncontrolled human data; no regulator has approved it for any indication.
Compare
Mechanism
In animal and cell models BPC-157 is reported to promote angiogenesis and tissue repair, interact with the nitric oxide (NO) system, exert antioxidant activity, and up-regulate growth-hormone-receptor expression in tendon fibroblasts. Its molecular targets and mechanism in humans remain poorly characterised, as almost all mechanistic work is preclinical.
Regulatory Status by Region
- United States (FDA)Not FDA-approved; barred from pharmacy compounding as a 503A Category 2 bulk drug substance (2023); no approved human indication. On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend BPC-157 (for ulcerative colitis) for the Section 503A Bulk Drug Substances List; the vote is advisory and non-binding, and the FDA had not made a final decision as of publication.
- Australia (TGA)Schedule 4 (Prescription Only Medicine) under the Poisons Standard (added to Schedule 4 effective 1 June 2024); no registered product, prescription/compounded supply only.
- European Union (EMA)No EMA marketing authorisation; not an approved medicine.
- WADAProhibited at all times under S0 (non-approved substances) since 2022; no therapeutic use exemption available.
Key Studies
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review (opens in a new tab) (Jozwiak et al., Pharmaceuticals 2025;18(2):185; PMID 40005999)
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (opens in a new tab) (Front. Pharmacol. 2021; PMCID PMC8275860)
- From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management (opens in a new tab) (Int. J. Mol. Sci. 2026;27(6):2876)
Related Clinical Trials
Related News & Research
- This Week in Peptide Research: Bone-Building Peptide Mechanisms, Real-World GLP-1 Data, and a Reproductive-Axis Cluster
- FDA Advisory Panel Recommends Six of Seven Peptides for Compounding, Rejects Emideltide
- FDA Advisory Panel Votes to Recommend Compounding of BPC-157, TB-500 and Four Other Peptides, Rejects Emideltide
- FDA Advisory Committee to Weigh Compounding of BPC-157 and Other Research Peptides
- FDA Scientists Question Evidence for Peptides Backed by RFK Jr. Ahead of Advisory Panel
Latest research
- Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. (opens in a new tab)
Current pain and headache reports · Aug 24, 2026
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine. (opens in a new tab)
The American journal of sports medicine · Aug 11, 2026
Common Questions
- What is BPC-157?
- BPC-157 is an experimental 15-amino-acid peptide that has shown wound-healing and tissue-repair effects in animal and cell studies but has not been proven safe or effective in adequate human trials. It is not approved as a medicine anywhere. In Australia it is a Schedule 4 (prescription-only) substance and it is banned in sport by WADA at all times.
- Is BPC-157 approved for medical use?
- BPC-157 is not an approved medicine and is subject to regulatory restrictions in one or more regions. United States (FDA): Not FDA-approved; barred from pharmacy compounding as a 503A Category 2 bulk drug substance (2023); no approved human indication. On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend BPC-157 (for ulcerative colitis) for the Section 503A Bulk Drug Substances List; the vote is advisory and non-binding, and the FDA had not made a final decision as of publication. European Union (EMA): No EMA marketing authorisation; not an approved medicine. Australia (TGA): Schedule 4 (Prescription Only Medicine) under the Poisons Standard (added to Schedule 4 effective 1 June 2024); no registered product, prescription/compounded supply only.
- How does BPC-157 work?
- In animal and cell models BPC-157 is reported to promote angiogenesis and tissue repair, interact with the nitric oxide (NO) system, exert antioxidant activity, and up-regulate growth-hormone-receptor expression in tendon fibroblasts. Its molecular targets and mechanism in humans remain poorly characterised, as almost all mechanistic work is preclinical.
- Is BPC-157 legal in Australia?
- BPC-157 in Australia (TGA): Schedule 4 (Prescription Only Medicine) under the Poisons Standard (added to Schedule 4 effective 1 June 2024); no registered product, prescription/compounded supply only.
- Is BPC-157 banned in sport?
- BPC-157 under the World Anti-Doping Agency (WADA) code: Prohibited at all times under S0 (non-approved substances) since 2022; no therapeutic use exemption available.